Valganciclovir (vgc) (DrugBank: Valganciclovir)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 331 | 特発性多中心性キャッスルマン病 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01441063 (ClinicalTrials.gov) | September 13, 2011 | 24/9/2011 | Tocilizumab for KSHV-Associated Multicentric Castleman Disease | Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease | Castleman Disease;Multicentric Castleman Disease;Giant Lymph Node Hyperplasia | Drug: Zidovudine;Drug: Tocilizumab;Drug: Valganciclovir (VGC) | National Cancer Institute (NCI) | NULL | Completed | 18 Years | N/A | All | 8 | Phase 2 | United States |